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Abstract 
Background  
Prisoners carry a greater burden of physical, communicable and psychiatric disease 
compared to the general population. Prison health care structures are complex and provide 
challenges and opportunities to engage a marginalised and poorly served group with health 
care including Hepatitis C Virus (HCV) screening, assessment and treatment. Optimising HCV 
management in prisons is a public health priority. Nurses are the primary healthcare 
providers in most prisons globally.  Understanding the barriers and facilitators to prisoner 
engaging in HCV care from the perspectives of nurses is the first step in implementing 
effective strategies to eliminate HCV from prison settings. 
Aim   
To identify the barriers and facilitators to HCV screening and treatment in Irish prisons from 
a nurse perspective and inform the implementation of a national prison-based HCV 
screening program. 
Methods  
A qualitative study using focus group methodology underpinned by grounded theory for 
analysis in a national group of nurse managers (n=12). 
Results  
The following themes emerged from the analysis; security and safety requirements 
impacting patient access, staffing and rostering issues, prisoŶ Ŷurses͛ skill set and concerns 
around phlebotomy, conflict between maintaining confidentiality and concerns for personal 
safety, peer workers, prisoŶers͛ lack of knowledge, fear of treatment and stigma, inter-
prison variations in prisoner health needs and health service delivery and priority, linkage to 
care, timing of screening and stability of prison life 
Conclusion 
  
Prison nurses are uniquely placed to identify barriers and facilitators to HCV screening and 
treatment in prisoners and inform changes to health care practice and policy that will 
optimise the public health opportunity that incarceration provides.  
 
Introduction  
Hepatitis C virus (HCV) infection is a major public health problem, causing a significant 
amount of liver related morbidity and mortality globally [1,2]. In Ireland, like other 
developed countries, injecting drug use (IDU) is now the main route of HCV transmission[3–
6].  
HCV infection of often described as a silent epidemic with less than half of those infected 
aware of their HCV status[7]. Recent advances in HCV treatment including, direct acting 
anti-virals (DAA), mobile elastography,  less restrictive treatment guidelines and the 
movement of treatment out of hospital based specialist services have revolutionised the 
HCV treatment landscape [8–11]. The WHO have declared HCV elimination by 2030 a key 
public health target[12].  
People who inject drugs (PWID) carry a much higher HCV disease burden than the general 
population with HCV prevalence estimates of over 50%[13–15]. The ongoing criminalisation 
of drug users ensures a high HCV prevalence among prison populations[16–19]. The 
prevention, identification and treatment of HCV infection have been identified as a key 
priority for prison healthcare[20,21].  
Prisoners have multiple risk factors for HCV acquisition including unsafe IDU, non-sterile 
tattooing, violent assault and the sharing of tooth brushes and hair clippers[16,22,23]. 
Sexual transmission between men who have sex with men (MSM) is also a concern in prison 
where condoms are not available[24]. A 2013  systematic review and meta-analysis  
reported a HCV incidence of  1.4 per 100-person years and 16.4 per 100-person years in 
detainees with a history of IDU [16] and a summary HCV prevalence estimate for general 
detainees of 26%, increasing to 64% in those with a history of IDU [16]. 
  
There are 3674 persons incarcerated in Ireland on any given day and the annual turnover of 
prisoners is 14,182[25].  High levels of IDU have been reported in both male (42%) and 
female (60%) prisoners[26]. A 2000 study estimated a HCV prevalence of 37% in the Irish 
prison population increasing to 81% % in those with a history of IDU [27].  A later (2014) 
study found a reduced HCV prevalence of 13%[26]. HCV screening in Irish prisons is ad hoc 
and there is no data available on the numbers of prisoners screened or treated for HCV 
infection annually[28]. Furthermore, there is no HCV- related educational material available 
to prisoners either at committal or during their period of incarceration.  
A number of studies (two Irish papers) have identified barriers and facilitators to HCV 
screening and treatment in PWID[29–33]. These barriers include; perceiving HCV infection 
to be a benign illness, having no symptoms, fear of investigations and treatment, lack of 
information on testing locations, not being referred for specialist care, ineligibility for 
treatment, competing priorities and fear of stigma. Enablers include; trusted relationships 
with health professionals, education on HCV infection and management, developing 
symptoms, family responsibilities, and wanting to progress from drug use. Prisoners 
experience many similar barriers and other unique ones related to incarceration, including a 
lack of proactive approaches to offering testing, fears and lack of knowledge about HCV infection, 
concerns about confidentiality and stigma, and lack of continuity of care in the event of transfer or 
release [34,35].  
International and national guidelines on prisoner health recommend that HCV screening and 
treatment be made an integral part of all prison health care systems[21,36]. Despite these 
recommendations and evidence that when made available HCV screening and treatment 
can be safely and successfully provided in prison settings, often prisoners are released back 
to their communities unaware of their HCV status and untreated[7]. 
Nurses provide the majority of health care in prisons and were introduced into the Irish 
prison health system in 1999[37]. They currently provide medical care in all 15 Irish prisons.  
Each location has a designated nurse manager who provides clinical and operational 
governance to the nursing service.  Nurses play a pivotal role in primary care delivery, 
addiction treatment and the management of blood borne virus (BBV) infections including 
HCV infection[37,38].  
  
This paper reports on the qualitative component of a larger European project to find and 
treat HCV infection among hard to reach vulnerable populations [39]. It complements the 
two previous Irish studies  reporting barriers to HCV management and adds to the small 
number of international prison-based studies in this area[34,40]. It is unique in reporting 
these from a nurse managers͛ perspective and being national in coverage.  
Methodology  
The nurse managers of all thirteen closed prisons in the Irish Prison Service (IPS) were 
invited to attend a focus group. This methodology was used because perspectives are more 
likely to be revealed by interaction and discussion with peers and for its utility in a real-life 
prison setting.  Ethical approval was obtained from the Mater Ethics Committee, Dublin and 
supported and endorsed by the Irish Prison Service (IPS) Ethics group. 
Following, a review of the literature on the topic, completion of a scoping review and 
consultation with the research group and national experts in the area a focus group guide 
was finalised. This guideline included a series of open-ended questions covering the 
following areas; experience of prison- based HCV screening and treatment, barriers and 
enablers to uptake, challenges related to incarceration and release, inter-prison variations in 
health care delivery and role of security staff and peers in prison HCV management. 
Twelve of the thirteen nurse managers participated in the focus group. All participants were 
given a participant information leaflet (PIL) to read and had an opportunity to ask questions 
before giving their informed consent to participate. The focus group lasted for a period of 90 
minutes. The group was moderated by researcher (DC) and observed by researcher (MCVH) 
from the research team. The focus group interview was recorded using an encrypted digital 
audio recorder, and observations of group dynamics and interactions were written in field 
notes during and after the event. 
All audio recordings were transcribed using Microsoft word and were uploaded to NVIVO 11 
for coding and thematic analysis. A grounded theory approach informed both the collection 
and analysis of the data. The thematic coding was revised with each analysis of the focus 
group narrative and analysis ceased when thematic saturation was achieved (agreed by 
  
researcher 1 and 2). Illustrative quotes from the recorded narratives supporting the 
thematic analysis are reported as either Dublin or Non-Dublin based. This is to protect the 
confidentiality of the participants.  
Results  
The following themes emerged from analysis of the data; security and safety, staffing and 
rostering issues, skill set and concerns regarding phlebotomy skills, conflict between 
maintaining confidentiality and concerns for personal safety, peer networks, prisoŶers͛ laĐk 
of knowledge, fear of treatment and stigma, inter-prison variations in prisoner health needs, 
health service delivery and priority, linkage to care, timing of screening and stability of 
prison life. 
Security and safety requirements impacting access to prisoners  
Many participants described the limitations that security and safety within their prisons 
placed on health care delivery. Accessing prisoners was often problematic in particular 
protection prisoners with heightened security requirements. Participants unanimously 
agreed that their professional ethics were never compromised and reported that security 
staff respected their roles. 
͞seĐuƌitǇ Đoŵes first and we may never get to see the prisoners͟. (Dublin) 
͞The aĐĐess to patieŶt gƌoup is so liŵited͟. (Non- Dublin) 
We ǁoƌk ǁell ǁith the pƌisoŶ offiĐeƌs aŶd goǀeƌŶoƌs, ǁe ƌespeĐt eaĐh otheƌ͛s ƌoles ... I Ŷeǀeƌ feel 
Đoŵpƌoŵised͟. (Dublin) 
Staffing and rostering issues  
Nurse managers reported lack of staffing as a barrier to provision of health care in their 
prisons. The structured rostering system based a three-month cycle (a quarter) often 
created staff deficits towards the end of the cycle. A number of duties are prioritised during 
periods of short staffing which included the completion of the committal interview and the 
  
dispeŶsiŶg of ŵediĐatioŶs. Blood ďorŶe ǀirus sĐreeŶiŶg ǁas ofteŶ ͞deŵoted͟ duriŶg these 
times. 
͞We͛ƌe Ŷot flushed ǁith staff to do it͟. (Non-Dublin) 
͞With ƌegaƌd to sĐƌeeŶiŶg, it͛s Ŷot sǇsteŵatiĐ it is ǀeƌǇ staff depeŶdaŶt͟. (Dublin) 
͞Phlebotomy lists have definitely gone doǁŶ oŶ the pƌioƌitǇ list ǁheŶ ǁe͛ƌe shoƌt staffed͟. (Non-
Dublin) 
͞We tend historically to be dangerously short of staff for protracted periods of time͟. (Non-Dublin) 
Generally, happens more at the start of each pool of overtime hours and rarely is the activity done at 
the eŶd ǁheŶ Ǉou͛ƌe ƌeallǇ shoƌt aŶd Ǉou͛ƌe ďaƌelǇ giving out the medication. So, it͛s Ƌuite spoƌadiĐ 
and opportunistic. (Dublin) 
Skillset and concerns regarding phlebotomy 
 Focus group participants identified that nurses working in the IPS had a specific skill set that 
matched the complex health needs of prisoners and was suited to caring for HCV infected prisoners 
through the screening and treatment process.  Knowledge of the local environment and how it 
impacting health care delivery was viewed as important.   
͞Theƌe͛s a paƌtiĐulaƌ skill set that is prison nursing ... knows the care plan of that individual, knows 
the dynamic of the environment and can support the patient through that treatment͟. (Dublin) 
 ͞We haǀe a wide variation of expertise amongst the nursing group .... many specialist interests as 
well. It makes perfect sense for infectious diseases or STIs; just as a Đohoƌt it ŵakes peƌfeĐt seŶse͟. 
(Non-Dublin) 
Fear of performing phlebotomy was identified by a number of participants. This was linked with the 
known high levels of BBV infection among prisoners, and the associated risks of needle stick injury. 
and fear that prisoners might use the needle as a weapon. Many nurses had not received 
phlebotomy training and of those who did were seen to lack confidence in conducting the 
procedure.  
  
͞Theƌe͛s a pƌoďleŵ of skill ŵiǆ. Lots of Ŷuƌses doŶ͛t take ďloods. If Ǉou haǀe ŶoďodǇ tƌaiŶed up that͛s 
a pƌoďleŵ. “oŵe Ŷuƌses aƌe afƌaid to take ďloods. Theƌe͛s a feaƌ. The ǀiƌus itself ...  people not 
ĐoŶfideŶt takiŶg ďloods͟. (Dublin) 
Conflict between maintaining confidentiality and concerns for personal safety 
Some participants expressed concerns about medical confidentiality in particular the 
presence of prison officers during the committal interview and during ward rounds. This was 
also linked with fear for personal safety. A number of participants expressed concerns about 
taking blood without the presence of security staff and the potential for needles to be used 
as weapons. Some participants felt conflicted between wishing to maintain confidentiality 
for the prisoners and the need to ensure personally safety.  
͞I think confidentiality is a huge thing͟. (Dublin) 
͞Theƌe aƌe seĐuƌitǇ issues though; I would not like to do it without an officer… I feel ĐoŶfliĐted͟. (Non-
Dublin) 
͞Yeah it is a ǁeapoŶ too͟. (Non-Dublin) 
͞There are some that you need two offices to deal with them so in that cases, different things for 
different prisoners͟. (Dublin) 
Peer networks 
There were mixed views in the group about the use of peer workers in prison health care 
including HCV screening and treatment. Many participants had worked with peers in mass 
screening initiatives and were very positive about their benefits. Concerns were expressed 
with regard to confidentiality, the accuracy of information being provided, the structures 
required to ensure governance and maintenance of prison security. 
͞We do a lot of screening through Red Cross initiatives (Peer workers). Suppose maybe we 
should do widespread screening as a once off time, might be worth it͟. (Dublin) 
͞They are not that confidential with other prisoners͟. ;DuďliŶͿ 
  
͞I think theƌe ǁould ďe ĐoŶĐeƌŶs … seĐuƌitǇ is a ƌeal oŶe… I think we need to be careful what we 
subcontract out. The information that is going to people … may not always be accurate. We have a 
ƌespoŶsiďilitǇ ǁheŶ people aƌe eŶgagiŶg ǁith tƌeatŵeŶt that ǁe͛ƌe providing really good 
information. (Dublin) 
͞I kŶoǁ peeƌ support can be great but we need to be careful with the role they can play and that we 
are not abdicating our role. The governance of it, the security issues, and the obligations we have 
must be considered you know͟. (Non-Dublin) 
 
PrisoŶers͛ laĐk of knowledge, fear of treatment and stigma 
Lack of knowledge among prisoners was seen as barriers to engagement with HCV care. This was 
also linked with fear of treatment including liver biopsy and interferon-based treatment regimes.  
͞The myths are still out there and it goes to show maybe we need to follow up on that͟. (Dublin) 
͞They (prisoners) ĐaŶ ďe the ďiggest ďloĐk Ŷot ďeĐause theǇ aƌe opposed to it ďut ďeĐause theǇ doŶ͛t 
have the knowledge͟. (Dublin) 
͞Most of the pƌisoŶeƌs doŶ͛t aĐtuallǇ kŶoǁ the diffeƌeŶĐe ďetǁeeŶ hepatitis A, B, C oƌ D. “o if ǁe ask 
have you hepatitis C? TheǇ saǇ ͚ǁhat͛s the diffeƌeŶĐe ͞? (Non-Dublin) 
͞“oŵe of the stories aďout ǁhat the treatŵeŶt is aŶd hoǁ that affeĐts people. I͛ǀe heard people say 
they͛ǀe relapsed ďeĐause of the treatŵeŶt, so there is that fear that Đoŵes iŶto it, you kŶoǁ ͚is that 
treatŵeŶt goiŶg to help or ŵake ŵe relapse͛? (Dublin) 
 PrisoŶers͛ ĐoŶĐerŶ arouŶd stigma was also seen as a block to prisoners engaging in HCV care. Many 
participants argued that making screening routine and universal had the potential to reduce this 
stigma. Participants were concerned about the maintenance of confidentiality and how this increased 
the fear that prisoners had about being stigmatised once their HCV status was known within the 
prison. 
͞It ďeĐoŵes suĐh a Ŷoƌŵal paƌt of ĐoŶǀeƌsatioŶ aŶd that ƌeallǇ helps to destigŵatise the ǁhole 
thiŶg͟. (Dublin) 
͞Is there still a stigma? I ... think there is. And voicing that within the prison or in the landing can still 
have the impact in someone coming forward or trying to come forward. How do you keep that 
confidential? How do they approach someone letting them know they can come and get tested 
without it being broadcasted across the landing͟? ;NoŶ-Dublin) 
͞You͛d see that͛d ďe the ďeautǇ iŶ uŶiǀeƌsal testiŶg, ďeĐause theŶ it͛s eǆpeĐted. It ǁould destigŵatise 
it.  (Dublin) 
  
Inter-prison variations in prisoner health needs and health service delivery and priority  
A consistent narrative emerging form the focus group discussion was a recognition of the 
heterogeneity of prison populations linked with differences in how health care was 
delivered at different locations.  Numerous references were made regarding Dublin prisons 
͞iŶside the pale͟ ǀersus other prisoŶs aŶd hoǁ resourĐes ǁere alloĐated. The tone of the 
narrative revealed a subtle undertone that Dublin based prisons have more resources 
allocated to them compared to other prisons. Some participants regarded resource 
allocation as ͞urban centric͟. 
͞Not a lot of theŵ, ǀeƌǇ little of theŵ ǁaŶt sĐƌeeŶiŶg aŶd ǁouldŶ͛t ĐlassifǇ theŵselǀes at ƌisk of 
haviŶg piĐked it up. OŶe is pƌoďaďlǇ the ŵost ǁe͛d eǀeƌ had oŶ tƌeatŵeŶt͟. (Non-Dublin) 
͞IŶ ŵǇ eǆpeƌieŶĐe, ǀeƌǇ little, oŶe in eight years since I͛ǀe ďeeŶ theƌe. We do a ŵodeƌate aŵouŶt of 
sĐƌeeŶiŶg aŶd it doesŶ͛t tuƌŶ up͟. (Non-Dublin) 
͞I feel that prisoners are not gettiŶg tƌeatŵeŶt ďeĐause theǇ͛ƌe outside of the DuďliŶ aƌea͟. (Non-
Dublin) 
͞Feel that they are prejudiced because they are outside of the M50͟. ;DuďliŶͿ 
͞It is very urban centric and then you get out of the urban areas … ŵoƌe ƌuƌal… aŶd ǁe aƌe not as 
invested and it is not as high profile͟. (Non- Dublin) 
Linkage to care  
A number of participants reported challenges with linkage to care and the short prison sentences 
served. This was of particularly challenging in remand and female prisoners. 
͞We sĐƌeeŶ, sĐƌeeŶ, sĐƌeeŶ. You kŶoǁ it͛s alŵost like a ƌoutiŶe ďut its ŵoǀiŶg it oŶ to tƌeatŵeŶt is 
the pƌoďleŵ͟. (Dublin) 
͞We͛ƌe doiŶg a lot of sĐƌeeŶiŶg ǁhiĐh thƌoǁs up a lot of people … ďut ǁheƌe to Ŷeǆt?͟ (Dublin) 
͞TheǇ ͚ƌe hardly in but they are gone home .... what do we do with the positive test then ͛͞. (Non-
Dublin) 
  
͞We haǀe a ǀeƌǇ ŶoŵadiĐ tǇpe of ĐlieŶt gƌoup so to tƌǇ aŶd haǀe theŵ foƌ the ƌeƋuiƌed tiŵe that is 
required to finish treatment you know... huge problems with a full course of treatment ...50% 
remand.  (Dublin) 
Participants who had access to in-reach hepatology services found that this had a positive impact on 
linkage to care. The presence of in-reach hepatology as seen as having the added benefit of 
increasing awareness of HCV a and keeping it a priority in prisons where it was available. This service 
was only available in three of the fifteen locations included in the study. The use of tele -medicine 
was seen as a facilitator to treatment uptake. It allowed easy and timely access to consultant care 
and reduced the need for patients to be brought to hospital reducing cost, risk and staffing 
requirements.  
͞DoiŶg it (tƌeatŵeŶt) in house makes a big difference because we have a hard to reach group, a high-
risk Đohoƌt͟. (Dublin) 
͞We haǀe deǀeloped that a little bit recently with a teleŵediĐiŶe liŶk so ǁe͛ǀe ƌeduĐed ouƌ tƌaŶspoƌt 
needs for consultant reviews͟. ;Dublin) 
IŶ ƌeaĐh has tƌaŶsfoƌŵed that. It͛s hugelǇ iŵpoƌtaŶt, that aĐĐessiďilitǇ. That ĐhaŶges hoǁ people 
thiŶk. It͛s foƌeŵost iŶ people͛s ŵiŶds. TheǇ͛ƌe ďeiŶg seeŶ. That ŵakes a huge diffeƌeŶĐe. (Dublin) 
͞The other thing we should be looking at is shared learning. Something like the echo model is 
something that would really be valuable in all prisons͟. (Dublin) 
Timing of screening  
There were mixed views on the  timing of screening. A number of participants favoured a routine, 
opt-out approach at committal others expressed concerns about prisoners having competing 
priorities at this time. Concerns were also expressed regarding staffing levels, time allocated to the 
committal process and the presence of security staff compromising confidentiality.  
͞OŶe of the thiŶgs to get ƌid of the ďaƌƌieƌs is ŵakiŶg it ƌoutiŶe at Đoŵŵittal, Ǉou ǁouldŶ͛t thiŶk 
tǁiĐe. That͛s pƌoďaďlǇ ǁheƌe ǁe Ŷeed to get to. The saŵe ǁaǇ as Ǉou eǆpeĐt to giǀe uƌiŶe͟. (Non-
Dublin) 
͞We doŶ͛t haǀe pƌoteĐted tiŵe foƌ Đoŵŵittal iŶteƌǀiew and that is a significant barrier to changing 
any type of comprehensive screening. The opportunity is lost. And you also have an officer standing 
iŶ the ƌooŵ so... ͞.  (Dublin) 
  
͞TheǇ͛ƌe all aĐtiǀelǇ seekiŶg ŵediĐatioŶ...sĐƌeeŶiŶg ďlood tests is so faƌ down the line of what they 
are thinking. Day after still all over the place...  two weeks later better when theǇ ͚re settled...͟. 
(Dublin) 
Stability of prison life 
All participants reported stability of prison life and access to medical care as a facilitator to 
prisoŶers͛ eŶgageŵeŶt iŶ HCV Đare.  Barriers to ĐoŵŵuŶity health Đare aĐĐess aŶd the ĐhaotiĐ pre-
incarceration lifestyles of many prisoners could be successful addressed and overcome in prison. 
͞Accessibility and stability. Access to nursing is 24/7, looking at holistic ... monitor weight loss ... all 
these things that have come up maybe in the community ...  not the easiest to engage in health 
care͟.  (Non-Dublin) 
 ͞“o, the stability ... the chaotic lives stop and the support network ... can wrap around that individual 
͞. (Dublin) 
Discussion  
This study provides a unique insight into Irish nurse managers͛ views on HCV screening and 
treatment in Irish prisons and other closed settings. Many of the themes identified in this 
research have been reported previously in the literature with regard to clinical provision and 
prison staff. Lack of knowledge, fear of treatment and concerns regarding stigma are known 
barriers to HCV infected PWID and prisoners engaging with HCV screening and 
treatment[29–31,40]. Many of these barriers are historical, related to interferon based 
treatments and have been removed by the newer DAA therapies [41–43]. Prison nurses are 
uniquely placed to engage prisoners in educational programs and health promotion is 
viewed as a core component of prison health care and prison nurse duties[20,38]. Identified 
opportunities for health promotion in prisons  include, advice on prevention of 
communicable  diseases,  modifying high-risk behaviours and measures to improve mental 
health [20]. Making HCV information leaflets available in all relevant languages across the 
IPS has the potential to increase awareness and engagement in HCV care among Irish 
prisoners.  
Prisons are designed for punishment, correction, rehabilitation and return to the community 
which at times can impact on the goals of health care. The concept of dual loyalty has been 
described in the literature and can cause conflict between security and health care staff 
[44].  This study reports the challenges that security requirements can pose on prisoner 
  
access. This was of particular relevance for protection prisoners, a growing cohort in Irish 
prisons due to an increasing gangland culture in Ireland[45]. Clinical independence is an 
essential component of health care provision and professionalism. The relationship between 
prison health care provider and prisoner is unequal and not based on free choice. The aims 
of incarceration can, at times, be in conflict with the provision of optimal prison healthcare. 
Independence of health care provision is recognised as a critical element for quality health 
care in prisons and is underpinned by international standards [20,44,46]. Many prisons fail 
to meet these standards because of, a lack of awareness, legal regulations, contradictory 
terms of employment for health care providers, or poor health care governance structures 
[46]. Irish nurses did not feel compromised in their clinical work and describe a respectful 
and collaborative relationship with their security colleagues. Irish nurse managers felt 
supported by prison officers and governors and describe a whole prison approach to health 
care delivery in Irish  prison as recommended by the WHO [20]. 
This study reports on the inter-prisoŶ ǀariatioŶ iŶ prisoŶers͛ health needs, levels of 
communicable disease, health care priorities and health care delivery in Irish prisons. 
Prisoners are often reported in the literature as a single homogenous group but it is 
recognised that there is much heterogeneity in prison populations globally[14,19,47]. This 
variation can be regional, between countries and even within different prisons in the same 
country. There is much variation in HCV infection in prisons globally and is directly linked 
with the numbers of PWID incarcerated at the location [16,17]. This variation was reported 
in the two previous Irish prison HCV studies and prison in Ireland are categorised in low, 
medium and high-risk prisons[26,48]. The majority of high risk prisons are Dublin 
based[26,48]. This variation in HCV prevalence and numbers of prisoners with a history of 
IDU   within Irish prison supports an institution specific response to screening and treatment 
informed by local community -based HCV treatment services, available resources and 
existing structures of health care delivery.  
This study highlights different approaches to and levels of HCV screening in Irish prisons. 
These variations are dependent on the perceived levels of HCV infection, available staffing 
and structures of health care delivery at different prison locations. The focus group 
narrative suggests an ad-hoc approach to screening, alongside difficulties in providing the 
  
treatment care continuum. Recent National HCV Screening Guidelines recommend that all 
prisoners should be offered HCV screening on entry to prison[28].  There was limited 
support within the focus group for this approach. A small number supported an opt-out 
approach to HCV screening at committal but the majority of participants expressed concerns 
about its feasibility. Staff shortage, limited time dedicated to the committal process, 
prisoners competing priorities at committal and concerns regarding confidentiality were 
identified as barriers. Fear, poor patient venous access, lack of training and confidence in 
phlebotomy skills and concerns for personal safety were other barriers identified to HCV 
screening by nurse managers. 
 It is recognised that venipuncture can be challenging in PWID due to poor venous access 
linked to intravenous drug use and associated medical complications [49]. Poor vascular 
health may require specialist staff to take blood, which if only available in hospital 
phlebotomy services can increase stigma, cost and security concerns for prisoners [50]. This 
identified barrier can be removed by the use of dried blood spot (DBS) testing which is non-
invasive and can be performed by clinical and non-clinical staff [51]. Two UK studies showed 
that offering DBS testing within specialist addiction services and prisons led to a threefold to 
six-fold increase in HCV testing [51,52]. A recent systematic review identified DBS as the 
best available targeted intervention for increasing HCV case-finding among PWID [53]. This 
approach to screening is cost -effective in prisons if continuity of treatment/care is ensured 
[54]. DBS testing should be considered in Irish prisons and has the potential to remove many 
of barriers to HCV screening identified in this study. Prisoners concerns regarding stigma 
was identified as a barrier to HCV care by many participants. Concerns regarding stigma 
experienced by HCV infected PWID and prisoners are well documented[29,33,40,55]. 
Maintaining complete medical confidentiality in prison settings can be a challenge[20]. 
Disclosure of a prisoner͛s HCV status may occur due to their attendance at certain clinics or 
having certain blood tests performed.  Adopting a standardised opt-out approach to HCV 
screening at committal across the IPS has the potential to increase screening uptake, reduce 
the stigma associated with declaring IDU and increase confidentiality [11,56].   
This study also highlighted the extra challenges encountered with remand prisoners. Like 
most prisoners globally the majority of Irish prisoners serve short prison 
  
sentences[7,25,57,58]. This is even more problematic among remand prisoners. Historically 
HCV treatment lengths were greater than sentence length. The advent of short acting 
pangenotypic DAA regimes has now revolutionised HCV treatment within prison 
settings[59,60]. Reducing treatment times to 8 weeks without negatively impacting 
treatment outcomes allows many more prisoners to complete treatment before release. 
Short prison sentences, while challenging, could also be viewed as an opportunity since 
large numbers of at risk and HCV infected people come in contact with the criminal justice 
system annually, providing a unique public health opportunity to engage this underserved 
and hard to reach cohort. 
This study identifies linkage to care as a challenge and reports a number of facilitators that 
improved treatment uptake post screening. These include in-reach hepatology services and 
the use of tele-medicine. These have been previously identified at enabling and improving 
linkage to care[61,62]. A comprehensive approach to prison HCV care has the potential to 
impact positively on community HCV management, but its effectiveness is dependent on 
community linkage on release[63] Transitioning from prison to community is seen as a high-
risk time for prisoners as they adapt to their community on release[7,64]. Ensuring that 
prisoners who have been screened or started treatment for HCV are linked to community 
services underpins the cost-effectiveness of most screening and treatment models adopted 
for prison HCV management[54,56,65]. 
This study highlights the complexity of peer involvement in prison health care.  Previous 
studies have shown that the use of peer workers in community-based HCV treatment has a 
positive impact on the uptake of services [8,66]. Research shows high levels of satisfaction 
among service users and staff in community-based drug treatment clinics with this role 
[66,67].  Peer workers can dispel the myths and fears associated with HCV treatment, 
reduce stigma, enhance mutual trust, increase social support, and increase knowledge and 
engagement in HCV care [32,66,68]. 
A large 2015 systematic review (mainly qualitative studies) of peer education and support in 
prison settings found that peer education interventions are, effective at reducing risk 
behaviours, acceptable within the prison environment and have a positive impact on 
prisoner wellbeing[67]. Peer workers have, the ability to connect with other prisoners, 
  
reduce social stigma and impact positively with a vulnerable patient cohort who are 
traditionally resistant to professional advice[67,69,70]. There are also direct benefits for the 
peer workers themselves and benefits for the wider prison system including, more effective 
use of resources and the ability to expand the range of prison-based health services 
available to inmates[70]. Research into cost-effectiveness is sparse [67]. Peer interventions 
in prisons can impact positively on health outcomes, but these effects are more well-defined 
for peer deliverers [67,69,71]. There is evidence to suggest that prison peer workers can be 
suďjeĐted to "ďurŶout͟ aŶd that superǀisory proĐesses Ŷeed to ďe ĐoŶsidered Đarefully iŶ 
order to avoid the intervention from being counter-productive [71]. It is recognised that 
peer interventions can have adverse effects on the security of prisons [69,70]. This security 
risk requires organisational support within the prison to ensure smooth implementation and 
safety of prisoners. Peer interventions cannot be seen as independent of prison life and 
health services need to work in partnership with prison services to deliver peer 
interventions [70]. 
The health needs of prisoners are diverse and can include: addiction, mental health and 
management of communicable diseases [18,23,33]. Prison healthcare provision is 
challenging for all staff and particularly for nurses who have to adapt to the security 
requirements of prison life.  The healthcare of prisoners is an integral aspect of 
incarceration. Healthcare (and nursing) in prisons in Ireland is based on a clearly-defined 
legal framework (the ͚PrisoŶ ‘ules͛Ϳ aŶd the IP“ has statutory respoŶsiďility for its delivery 
[72]. Nurses working in the IPS have a wide range of professional experience and 
qualifications. Their clinical role is diverse and encompasses a wide range of responsibilities 
and functions. The unique skill set of Irish prison nurses was identified in this study. 
Participants reported that Irish prison nurses were uniquely placed to manage and care for 
prisoners in a holistic fashion and with their knowledge and understanding of local prison 
regimes were well placed to upscale HCV care across the Irish prison estate. This study 
highlighted a deficit in phlebotomy training among some nurses. This is of concern given the 
high rates of BBV infections and the risk of transmission through needle stick injury[16,73]. 
This training deficit will need to be addressed by the IPS as a matter of urgency. Participants 
did not address knowledge or experience of post exposure prophylaxis ((PEP) in the focus 
group. This is an area that warrants further investigation.  
  
The use of focus group methodology allowed this study to have a national coverage which is 
a major strength with regard to the generalisablity of its findings. It is also a practical and 
acceptable way to conduct research in real life prison settings. The interaction among 
participants during the group provided the opportunity for an in-depth exploration of topics.  
Researcher 1 (DC) was known to most focus group participants which may have impacted on 
their willingness to fully disclose their views. The recruitment of only nurse managers as 
participants may not reflect the experiences of front-line prison nurses so its findings may 
not fully represent the views of Irish prison nurses on HCV in Irish prison. The researchers 
reported the findings in a manor to ensure the confidentiality of all participants so reporting 
the narratives as either Dublin or Non -Dublin does not fully reveal the uniqueness and 
differences between different prison settings. Demographics such as age, gender and length 
of time in service were not collected since these were deemed to be too sensitive to collect 
in a work environment and so we cannot report and compare the narratives according to 
age, gender or of length of time in service.  
Conclusion 
Nurses are the main providers of health care in Irish prisons. They work in a very complex 
work environment where they have to navigate the struggle between custody and caring. 
Often correctional priorities override nursing and health care priorities. Uniquely they face 
safety and security concerns daily. This study identifies many challenges to prison-based 
HCV screening and treatment including; fear of treatment and stigma, lack of knowledge, 
reduced staffing, security and custodial requirements taking priority over health care 
delivery, poor venous access coupled with poor phlebotomy skills, short sentence length 
and linkage to care. Identification of these barriers can inform changes to Irish prison health 
care practice and policy including; the introduction of DBS, opt-out screening at committal, 
the use of 8-week pangenotypic DAA regimes as close to committal as possible and the 
expansion of in-reach hepatology services and tele-medicine. The recognised heterogeneity 
of prison populations and associated differences in health care delivery will require a 
location specific approach to HCV management. Prison peer workers have the potential to 
impact positively on the delivery of health and HCV care in prisons but needs a well 
organised structure to provide support, governance and manage security concerns. 
  
Engaging nurse managers and nurses in the planning and implementation of prison-based 
HCV management will optimise the public health opportunity that incarceration provides. 
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